These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18325673)

  • 1. Effects of varied doses of psilocybin on time interval reproduction in human subjects.
    Wackermann J; Wittmann M; Hasler F; Vollenweider FX
    Neurosci Lett; 2008 Apr; 435(1):51-5. PubMed ID: 18325673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of psilocybin on time perception and temporal control of behaviour in humans.
    Wittmann M; Carter O; Hasler F; Cahn BR; Grimberg U; Spring P; Hell D; Flohr H; Vollenweider FX
    J Psychopharmacol; 2007 Jan; 21(1):50-64. PubMed ID: 16714323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.
    Carbonaro TM; Johnson MW; Hurwitz E; Griffiths RR
    Psychopharmacology (Berl); 2018 Feb; 235(2):521-534. PubMed ID: 29116367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow.
    Lewis CR; Preller KH; Kraehenmann R; Michels L; Staempfli P; Vollenweider FX
    Neuroimage; 2017 Oct; 159():70-78. PubMed ID: 28711736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The impact of psilocybin on visual perception and spatial orientation--neuropsychological approach].
    Jastrzebski M; Bala A
    Psychiatr Pol; 2013; 47(6):1157-67. PubMed ID: 25007546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-response relationships of psilocybin-induced subjective experiences in humans.
    Hirschfeld T; Schmidt TT
    J Psychopharmacol; 2021 Apr; 35(4):384-397. PubMed ID: 33663259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
    Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
    J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition.
    Barrett FS; Carbonaro TM; Hurwitz E; Johnson MW; Griffiths RR
    Psychopharmacology (Berl); 2018 Oct; 235(10):2915-2927. PubMed ID: 30062577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.
    Rucker JJ; Marwood L; Ajantaival RJ; Bird C; Eriksson H; Harrison J; Lennard-Jones M; Mistry S; Saldarini F; Stansfield S; Tai SJ; Williams S; Weston N; Malievskaia E; Young AH
    J Psychopharmacol; 2022 Jan; 36(1):114-125. PubMed ID: 35090363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations.
    Kometer M; Pokorny T; Seifritz E; Volleinweider FX
    Psychopharmacology (Berl); 2015 Oct; 232(19):3663-76. PubMed ID: 26231498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study.
    Marschall J; Fejer G; Lempe P; Prochazkova L; Kuchar M; Hajkova K; van Elk M
    J Psychopharmacol; 2022 Jan; 36(1):97-113. PubMed ID: 34915762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic Functional Hyperconnectivity After Psilocybin Intake Is Primarily Associated With Oceanic Boundlessness.
    Mortaheb S; Fort LD; Mason NL; Mallaroni P; Ramaekers JG; Demertzi A
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 Jul; 9(7):681-692. PubMed ID: 38588855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin.
    Schartner MM; Carhart-Harris RL; Barrett AB; Seth AK; Muthukumaraswamy SD
    Sci Rep; 2017 Apr; 7():46421. PubMed ID: 28422113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan.
    Carbonaro TM; Johnson MW; Griffiths RR
    Psychopharmacology (Berl); 2020 Aug; 237(8):2293-2304. PubMed ID: 32500212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans.
    Stenbæk DS; Madsen MK; Ozenne B; Kristiansen S; Burmester D; Erritzoe D; Knudsen GM; Fisher PM
    J Psychopharmacol; 2021 Apr; 35(4):459-468. PubMed ID: 33501857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial.
    Yanakieva S; Polychroni N; Family N; Williams LTJ; Luke DP; Terhune DB
    Psychopharmacology (Berl); 2019 Apr; 236(4):1159-1170. PubMed ID: 30478716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.
    Studerus E; Kometer M; Hasler F; Vollenweider FX
    J Psychopharmacol; 2011 Nov; 25(11):1434-52. PubMed ID: 20855349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval.
    Vollenweider FX; Csomor PA; Knappe B; Geyer MA; Quednow BB
    Neuropsychopharmacology; 2007 Sep; 32(9):1876-87. PubMed ID: 17299516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.
    Griffiths RR; Johnson MW; Richards WA; Richards BD; McCann U; Jesse R
    Psychopharmacology (Berl); 2011 Dec; 218(4):649-65. PubMed ID: 21674151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations of consciousness and mystical-type experiences after acute LSD in humans.
    Liechti ME; Dolder PC; Schmid Y
    Psychopharmacology (Berl); 2017 May; 234(9-10):1499-1510. PubMed ID: 27714429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.